PB0239 - Pediatric Primary Immune Thrombocytopenia: Observation in Armenia

Sunday, July 10, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: Virtual

Presenting Author(s)

Henrik Arshak Grigoryan, MD

Clinical resident
Yerevan State Medical University after M. Heratsi, Pediatric Oncology and Hematology, Pediatric Cancer and Blood Disorders Center of Armenia, Hematology Center after Prof. R.H. Yeolyan, Yerevan, Armenia
Yerevan, Yerevan, Armenia

Co-Author(s)

AA

Anna Avagyan

Fellow
Yerevan State Medical University after M. Heratsi, Pediatric Oncology and Hematology, Yerevan, Armenia, Pediatric Cancer and Blood Disorders Center of Armenia, Hematology Center after Prof. R.H. Yeolyan, Yerevan, Armenia
Yerevan, Yerevan, Armenia
CS

Clodet Stepanyan

Fellow
Yerevan State Medical University after M. Heratsi, Pediatric Oncology and Hematology, Yerevan, Pediatric Cancer and Blood Disorders Center of Armenia, Hematology Center after Prof. R.H. Yeolyan, Yerevan, Armenia
Yerevan, Yerevan, Armenia
SH

Shushan Hovsepyan

Fellow
Yerevan State Medical University after M. Heratsi, Pediatric Oncology and Hematology, Yerevan, Pediatric Cancer and Blood Disorders Center of Armenia, Hematology Center after Prof. R.H. Yeolyan, Yerevan, Armenia
Gyumri, Shirak, Armenia
LV

Lala Vagarshakyan

Hematologist-oncologist
Yerevan State Medical University after M. Heratsi, Pediatric Oncology and Hematology, Yerevan, Armenia, Hematology Center after Prof. R.H. Yeolyan, Yerevan, Armenia,Pediatric Cancer and Blood Disorders Center of Armenia, Hematology Center after Prof. R.H. Yeolyan, Yerevan, Armenia
Yerevan, Yerevan, Armenia
GT

Gevorg N. Tamamyan

Head of the Department of Pediatric Oncology and Hematology, Yerevan State Medical University
Armenian Hemophilia and Thrombosis Treatment center
Yerevan, Yerevan, Armenia
LH

Liana Hambardzumyan

Background: Primary immune thrombocytopenia (ITP) is the most common form of thrombocytopenia in children. The incidence is 50 cases per 1,000,000 children per year.

Aims: The endpoint of this study is to identify the incidence of ITP among children receiving treatment at the Hematology center after Prof. Yeolyan, only center in Armenia, between January 2016 and December 2020.

Methods: We collected and analyzed the data of 176 children (≤18y/o) of whom 96 (54.5%) were male. The median age was 3.75 years. In the age groups less than 1, 1–5, and older than 5 years there were 31 (17.6%), 78 (44.3%) and 67 (38.1%) patients, respectively.

Results: The median platelet count was 6x10 9/L. Chronic ITP was observed in 31 (17.6%) children, persistent ITP in 14 (8%) and newly diagnosed in 131 (74.4%) patients. In the < 1-year-old age group newly diagnosed, persistent and chronic ITP were 28 (90.3%), 3 (9,7%) and 0 children, 1-5 years old patients 64 (82.1%), 4 (5.1%), 10 (12.8%), and >5-year-old patients 39 (58.2%), 7 (10.5%), 21 (31.3%), respectively.
First-line treatment was corticosteroids for 148 (84.1%) of whom 60 received Prednisolone (4mg/kg 4-7 days) and 89 Prednisolone (2mg/kg 2-3 weeks). Three patients received IVIG (one of them with glucocorticoids), four didn’t received any treatment and 22 (11.5%) received only symptomatic treatment (Etamsylate, Ascorbic acid). After the first course of glucocorticoids 106 patients platelet count increased (>100x10 9/L). Four patients with chronic ITP underwent splenectomy, results were satisfying and platelet count increased.

Conclusion(s): Although the cohort was retrospective, our data showed the incidence of ITP corresponds to the range reported in the literature.